Please note that the discussion on today's call includes certain non-GAAP financial measures, including adjusted EBITDA and adjusted net income. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP metric is available in our earnings release, which is available on our website at www.admabiologics.com. Our second quarter results reflect strong execution across the business and demonstrate the power of ASCENIV's long-term growth trajectory. ASCENIV demand accelerated during the second quarter, and June delivered the strongest sequential utilization growth we have experienced since the first half of 2024.
As we have discussed previously, distributor-reported end-user utilization remains our leading indicator of continued revenue growth. Based on the end market utilization data we continuously review, we believe current ASCENIV inventory levels remain appropriate and are consistent with underlying demand. immunoglobulin market, BIVIGAM demand stabilized during the quarter, resulting in sequential improvements in both utilization and revenue. We continue to maintain our disciplined approach that prioritizes durable, profitable growth over unsustainable discounting and other incentives.
Increasing physician adoption, new patient starts, and record utilization further demonstrate the relative insulation provided by ASCENIV's differentiated product profile and its positioning among later line, refractory, and medically complex primary immunodeficiency patients. Operationally, we believe we are well-positioned to support the continued revenue growth. Our yield-enhanced manufacturing process remains embedded in commercial production and continues to support product availability, manufacturing efficiency, and margin performance. Our diversified plasma sourcing strategy provides reliable access to high-titer plasma, and we believe our current supply infrastructure is sufficient to support anticipated demand.